On a reported annual basis, revenue went from KRW 2 billion in 2022 to KRW 215 million in 2023 (down 89.2% year on year), then to KRW 17.7 million in 2024 (down 91.8%), before recovering to KRW 228 million in 2025 (up 1,186.7%). Among 2022 to 2025, 2022 was the largest year and 2024 the smallest.
The operating loss widened every year, from KRW 11 billion in 2022 to KRW 13.2 billion, KRW 15.1 billion and KRW 15.8 billion in 2025, and the company has reported losses for four consecutive years from 2022 through 2025.
The net loss attributable to controlling shareholders grew from KRW 10.7 billion in 2022 to KRW 15.5 billion in 2025, and the total net loss including non-controlling interests was reported at the same amounts.
The operating margin was -551.5% in 2022, -6,145.5% in 2023, -85,523.5% in 2024 and -6,952.9% in 2025, reflecting losses that were very large relative to revenue. Reports attributed the operating loss mainly to the burden of drug-development costs.
Operating cash flow was negative every year, at -KRW 7.95 billion in 2022, -KRW 13 billion in 2023, -KRW 16.7 billion in 2024 and -KRW 14.5 billion in 2025.
The debt ratio fell from 20.1% in 2022 to 31.7% in 2023, 20.5% in 2024 and 12.7% in 2025, and at the end of 2025 total equity of KRW 24.7 billion was entirely attributable to controlling shareholders, against total liabilities of KRW 3.13 billion.
On a quarterly basis, revenue was KRW 168 million in Q3 2025, KRW 48.42 million in Q4 2025, KRW 65.4 million in Q1 2026 and KRW 41.17 million in Q2 2026, then jumped to KRW 4.63 billion in Q3 2026, up 11,148.5% from the prior quarter and 2,663.6% from a year earlier.
The operating loss in Q3 2026 was KRW 3.91 billion, narrower than KRW 4.39 billion in Q3 2025 but wider than KRW 3.11 billion in Q2 2026. Revenue rose to KRW 4.63 billion while an operating loss remained, which means the profit from the consolidated beauty business did not offset research and administrative costs.
Over the last four quarters, from Q4 2025 through Q3 2026, the net loss attributable to controlling shareholders totaled KRW 15.6 billion.